you are viewing a single comment's thread.
Any experienced biotech investor is aware of the inevitability of secondaries. Are secondaries all that bad as the money does goes on the books? I'm new to the board but I'm sure you're talking your book by stating the obvious.
the secondary just offered by ZIOP was a huge buying opportunity, so funny how this poster paints it as such a negative.....i guess we know your tactics now?
when was there a secondary? how many shares?